Real-world off-label use of icatibant for acute management of non-hereditary angioedema

被引：3

作者：

Thanh-Thao Le ^{[1
]}

Smith, William ^{[1
]}

Hissaria, Pravin ^{[2
]}

机构：

[1] Royal Adelaide Hosp, Clin Immunol, Allergy Dept, Port Rd, Adelaide, SA 5000, Australia

[2] SA Pathol, Human Immunol, Adelaide, SA, Australia

来源：

INTERNAL MEDICINE JOURNAL | 2021年 / 51卷 / 03期

关键词：

icatibant; bradykinin‐ mediated angioedema; ACE‐ inhibitor angioedema; angioedema acute management;

D O I：

10.1111/imj.15241

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

We retrospectively examined the indications and efficacy of off-label use of the bradykinin B2 receptor antagonist icatibant. The clinical heterogeneity, variability of response to icatibant and lack of efficacy of adrenaline described in this audit highlights both the need for biomarkers that can rapidly distinguish between histaminergic and non-histaminergic angioedema, and for guidelines to improve the utility of icatibant in the non-hereditary angioedema setting.

引用

页码：419 / 423

页数：5

共 50 条

[1] Real-world evidence for off-label intravenous thrombolysis in acute ischaemic stroke
Tsivgoulis, G.
Lioutas, V-A.
[J]. EUROPEAN JOURNAL OF NEUROLOGY, 2018, 25 (02) : 213 - 214
[2] Real-World Outcomes In Hereditary Angioedema: Experience From The Icatibant Outcome Survey In The United Kingdom
Longhurst, Hilary
Dempster, John
Lorenzo, Lorena
Buckland, Matthew
Grigoriadou, Sofia
Fabien, Vincent
Bangs, Catherine
Helbert, Matthew
[J]. CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 2015, 182 : 10 - 11
[3] Treatment of hereditary angioedema with icatibant: Efficacy in clinical trials versus effectiveness in the real-world setting
Maurer, Marcus
Longhurst, Hilary J.
Fabien, Vincent
Li, H. Henry
Lumry, William R.
[J]. ALLERGY AND ASTHMA PROCEEDINGS, 2014, 35 (05) : 377 - 381
[4] Off-label use of intravenous thrombolysis for acute ischemic stroke: a critical appraisal of randomized and real-world evidence
Tsivgoulis, Georgios
Kargiotis, Odysseas
De Marchis, Gianmarco
Kohrmann, Martin
Sandset, Else Charlotte
Karapanayiotides, Theodore
de Sousa, Diana Aguiar
Sarraj, Amrou
Safouris, Apostolos
Psychogios, Klearchos
Vadikolias, Konstantinos
Leys, Didier
Schellinger, Peter D.
Alexandrov, Andrei V.
[J]. THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS, 2021, 14
[5] Real-World Use of Off-Label MVASI in the Treatment of Patients With Neovascular AMD and DME
Lombardo, Marco
Missiroli, Filippo
Cerri, Luca
Sorge, Roberto P.
Cesareo, Massimo
Ricci, Federico
[J]. TRANSLATIONAL VISION SCIENCE & TECHNOLOGY, 2024, 13 (07):
[6] EARLY ICATIBANT TREATMENT IS ASSOCIATED WITH FASTER RESOLUTION OF HEREDITARY ANGIOEDEMA ATTACKS: REAL-WORLD DATA FROM THE ICATIBANT OUTCOME SURVEY
Longhurst, H.
Caballero, T.
Zanichelli, A.
Aberer, W.
Fabien, V.
Bouillet, L.
Maurer, M.
[J]. ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2013, 111 (05) : A47 - A48
[7] Management of acute attacks of hereditary angioedema: potential role of icatibant
Longhurst, Hilary J.
[J]. VASCULAR HEALTH AND RISK MANAGEMENT, 2010, 6 : 795 - 802
[8] Multiple drugsNon-hereditary angioedema and off-label use: 14 case reports
[J]. Reactions Weekly, 2021, 1865 (1) : 303 - 303
[9] Real-world outcomes in hereditary angioedema: first experience from the Icatibant Outcome Survey in the United Kingdom
Longhurst, Hilary J.
Dempster, John
Lorenzo, Lorena
Buckland, Matthew
Grigoriadou, Sofia
Symons, Christine
Bethune, Claire
Fabien, Vincent
Bangs, Catherine
Garcez, Tomaz
[J]. ALLERGY ASTHMA AND CLINICAL IMMUNOLOGY, 2018, 14
[10] Real-world outcomes in hereditary angioedema: first experience from the Icatibant Outcome Survey in the United Kingdom
Hilary J. Longhurst
John Dempster
Lorena Lorenzo
Matthew Buckland
Sofia Grigoriadou
Christine Symons
Claire Bethune
Vincent Fabien
Catherine Bangs
Tomaz Garcez
[J]. Allergy, Asthma & Clinical Immunology, 14

← 1 2 3 4 5 →